Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ANIX
ANIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANIX News
Anixa Biosciences Updates on Ovarian Cancer CAR-T Trial Outcomes
6d ago
Benzinga
Anixa Biosciences' CAR-T Therapy Receives Naming Approval
Feb 02 2026
PRnewswire
Anixa Biosciences CAR-T Therapy Receives Naming Approval
Feb 02 2026
Newsfilter
Anixa Secures Mexican Patent for Breast Cancer Vaccine
Jan 27 2026
PRnewswire
Anixa Biosciences Declines Following Phase 1 Results for Breast Cancer Vaccine
Dec 12 2025
SeekingAlpha
Anixa Biosciences' Phase 1 Study Shows Breast Cancer Vaccine is Safe and Well Tolerated
Dec 12 2025
NASDAQ.COM
Anixa Biosciences Vaccine Trial Achieves 74% Immune Response in Phase 1 Study
Dec 11 2025
PRnewswire
Anixa Biosciences Reports 74% Immune Response in Phase 1 Breast Cancer Vaccine Trial
Dec 11 2025
Newsfilter
Anixa Biosciences CEO to Join Investor Fireside Chat on Dec 15, 2025
Dec 10 2025
PRnewswire
Anixa Biosciences CEO to Discuss Breast Cancer Vaccine Data on December 15
Dec 10 2025
Newsfilter
Anixa Biosciences Receives WHO Approval for International Non-Proprietary Name of CAR-T Therapy, Signifying Major Step Towards Global Recognition and Future Market Launch
Nov 17 2025
Newsfilter
Water Tower Research Releases Statement on Technical Issues During Anixa Biosciences Fireside Chat
Nov 12 2025
Newsfilter
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Nov 12 2025
PRnewswire
Anixa Biosciences to Join Water Tower Research Fireside Chat on November 11, 2025
Nov 10 2025
Newsfilter
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Nov 05 2025
PRnewswire
Anixa Biosciences to Showcase at Spartan Capital Securities' Second Annual Investor Conference
Oct 23 2025
Newsfilter
Show More News
